HistoSonics’ unique histotripsy platform will fundamentally change the nature of surgery. Histotripsy uses the mechanical (not thermal) properties of focused ultrasound to precisely destroy targeted tissues without damaging surrounding tissue or structures.
Christine is the CEO of Histosonics, a life sciences startup based in Ann Arbor. HistoSonics is leading the coming revolution in histotripsy, a non-invasive, non-thermal surgery that will reduce patient trauma and healthcare costs across multiple indications.
Comments